Protherics DigiFab approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Protherics DigiFab (digoxin immune Fab, ovine) is approved Aug. 31 for "treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose." The company expects to delay launch of the product until June 2002 so it can focus on increasing production of its rattlesnake antivenom CroFab (crotalidae polyvalent immune Fab, ovine). Worldwide DigiFab sales could reach $30 mil., the company estimates